EQS-News: Immunic Reports Positive Interim Data from Phase 2

Issuer: Immunic, Inc. / Key word(s): Study results Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis 09.10.2023 / 22:01 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Reports Positi...

Related Keywords

United States , Russia , Switzerland , Ukraine , America , Andreas Muehler , Jessica Breu , Edna Kaplan , Jens Kuhle , Paula Schwartz , Daniel Vitt , University Hospital Basel , Program In Relapsing Multiple Sclerosis Ongoing , Sclerosis Centre , Immunic Inc , Distribution Services , Rx Communications Group , Exchange Commission , Nasdaq , Reports Positive Interim Data , Vidofludimus Calcium , Progressive Multiple Sclerosis , Week Data , First Half , Patients Shows Improvements , Biomarker Nfl , Consistent Throughout , Overall Progressive Multiple Sclerosis Population , All Subtypes , Nfl Effect , Neuroprotective Potential , Brain Volume Data , Cohort Expected , Relapsing Multiple Sclerosis Ongoing , Conference Call , Held Tomorrow , Senior Physician , Neuroimmunology Unit , Multiple Sclerosis Centre , Chief Executive Officer , Chief Medical Officer , North America , Private Securities Litigation Reform Act , Annual Report , Investor Relations , Corporate News , Regulatory Announcements , Positive , Interim , Data , Hase , Calliper , Trial , Idofludimus , Calcium , Progressive , Multiple , Clerosis , Et Cest , The , Reports , Apositi ,